There are currently two funded projects:

1) Characterization of the commercial multiple myeloma cell lines (Project Overview) (Project Status)

This project is a follow-up to the Multiple Myeloma Genomics Initiative (MMGI), which involved the characterization of 250 myeloma patient samples using Agilent 244k aCGH microarrays, Affymetrix U133Plus2.0 genechips, and whole genome sequencing. The MMGI identified a large number of potential leads, however, we do not know which of the model systems available for this disease are good models for the various "hits". The goal of this project is to characterize the 32 commercially available cell lines so investigators around the world can order the appropriate models to follow-up the results of the MMGI

2) Consequences of KDM6A/UTX inactivation in myeloma

One of the best "hits" in the MMGI was KDM6A, which is putative histone H3 lysine 27 (H3K27) demethylase and appears to be a tumor suppressor in multiple myeloma and a number of other malignancies. The goal of this project is to identify the genes which are being effected by KDM6A inactivation.